According to Brook Jackson, a whistleblower who worked on Pfizer’s Phase 3 COVID jab trial in the fall of 2020, data were falsified, patients were unblinded, the company hired poorly trained people to administer the injections, and follow-up on reported side effects was significantly delayed.
Jackson claims she repeatedly informed her superiors of poor laboratory management, patient safety concerns and data integrity issues. When she realized her concerns were ignored, she finally filed a complaint with the U.S. Food and Drug Administration. In her complaint to the FDA, Jackson listed a dozen incidents of concern, including the following:
- Participants were not monitored by clinical staff after receiving the shot
- Patients who experienced adverse effects were not promptly evaluated and protocol deviations were not being reported
- The Pfizer injection vials were stored at improper temperatures
- Laboratory specimens were mislabeled
We do know, however, that none of the problems Jackson raised in her complaint to the FDA were noted or addressed in Pfizer’s briefing document, submitted to the FDA’s advisory committee meeting December 20, 2020, when its emergency use authorization application was reviewed.
The FDA went ahead and gave the Pfizer jab emergency use authorization the very next day, despite being in receipt of Jackson’s complaint, which ought to have put the brakes on the FDA’s authorization. At bare minimum, they should have investigated the matter before proceeding.
“The point I am trying to make is very simple,” Doshi said. “The data from COVID vaccines are not available and won’t be available for years. Yet, we are not just ‘asking’ but ‘mandating’ millions of people to take these vaccines … Without data, it’s not science.”